Oxpentifylline for Treating Erythropoietin-Resistant Anemia
Author Information
Author(s): David Wayne Johnson, Carmel Mary Hawley, Brenda Rosser, Elaine Beller, Charles Thompson, Robert G Fassett, Paolo Ferrari, Stephen MacDonald, Eugenie Pedagogos, Alan Cass
Primary Institution: Australian Kidney Trials Network, School of Population Health, University of Queensland, Brisbane, Australia
Hypothesis
Oxpentifylline administration will effectively treat erythropoietin- or darbepoietin-resistant anaemia in chronic kidney disease patients.
Conclusion
The study aims to determine if oxpentifylline is a safe and effective treatment for anemia in chronic kidney disease patients who do not respond to standard therapies.
Supporting Evidence
- Oxpentifylline has been used for over twenty years for vascular diseases.
- Previous studies suggest oxpentifylline may improve hemoglobin levels in patients with ESA-resistant anemia.
- The study aims to recruit 110 patients to ensure adequate statistical power.
Takeaway
This study is testing if a medicine called oxpentifylline can help people with kidney problems who have anemia that doesn't get better with usual treatments.
Methodology
The study is a randomized, double-blind, placebo-controlled trial involving patients with stage 4 or 5 chronic kidney disease and significant anemia.
Potential Biases
There is a risk of selection, observer, and co-intervention biases.
Limitations
The study may be limited by potential biases and the need for adequate controls.
Participant Demographics
Adults aged 18 and over with stage 4 or 5 chronic kidney disease.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website